

WHAT IS CLAIMED IS:

- 1 1. A method for treatment or prevention of an angioproliferative condition which  
2 comprises administering to a patient experiencing said angioproliferative  
3 condition a pharmaceutically effective amount of a proteinase to exert an  
4 angiostatic effect.
- 1 2. The method according to claim 1 wherein said angioproliferative condition is a  
2 carcinoma, sarcoma, melanoma, ocular retinopathy, retrolental fibroplasia,  
3 psoriasis, angiofibromas, endometriosis, hemangioma, rheumatoid arthritis,  
4 capillary proliferation within atherosclerotic plaque, or a combination of such  
5 disorders.
- 1 3. The method according to claim 1 wherein said proteinase is derived from a  
2 bacterium.
- 1 4. The method according to claim 3 wherein said bacterium is *Porphyromonas*  
2 *gingivalis*.
- 1 5. The method according to claim 4 wherein said protease is PrtP, HagA, other  
2 cysteine proteinase, a HagArep peptide, a fragment or active site thereof, or DNA.
- 1 6. A composition for treatment or prevention of an angioproliferative condition  
2 comprising a pharmaceutically effective amount of a proteinase and an excipient  
3 for administration to a patient afflicted with said angioproliferative disorder.
- 1 7. The composition according to claim 6 wherein said angioproliferative condition is  
2 a carcinoma, sarcoma, melanoma, ocular retinopathy, retrolental fibroplasia,  
3 psoriasis, angiofibromas, endometriosis, hemangioma, rheumatoid arthritis,

- 4 capillary proliferation within atherosclerotic plaque, or a combination of such  
5 disorders.
- 1  
1 8. The composition according to claim 6 wherein said proteinase is derived from a  
2 bacterium.
- 1  
1 9. The composition according to claim 8 wherein said bacterium is *Porphyromonas*  
2 *gingivalis*.
- 1  
1 10. The composition according to claim 9 wherein said protease is PrtP, HagA, other  
2 *P. gingivalis* proteinase, a HagArep peptide, a fragment or active site thereof, or  
3 DNA
- 1  
1 11. A method for selectively treating an angioproliferative condition which comprises  
2 contacting the vasculature supplying a biological structure affected by said  
3 angioproliferative condition with an angiostatically effective amount of a  
4 protease.
- 1  
1 12. The method according to claim 11 wherein said proteinase is contacted with the  
2 basolateral surface of said vasculature.
- 1  
1 13. The method according to claim 11 wherein said angioproliferative condition is a  
2 carcinoma, sarcoma, melanoma, ocular retinopathy, retrolental fibroplasia,  
3 psoriasis, angiofibromas, endometriosis, hemangioma, rheumatoid arthritis,  
4 capillary proliferation within atherosclerotic plaque, or a combination of such  
5 disorders.
- 1  
1 14. The method according to claim 12 wherein said protease is derived from a  
2 bacterium.
- 1

Sub  
Ba

Handwritten signature/initials

16. The method according to claim 15 wherein said protease is PrtP, HagA, other proteinase a HagArep peptide, a fragment or active site thereof, or DNA..

17. A method for potentiating the effects of a chemotherapeutically effective agent which comprises co-administering said chemotherapeutically effective agent in the presence of a protease effective to disrupt cell-cell adhesion, cell-matrix adhesion, or both.

18. A method for preventing the implantation or sustenance of a fertilized ovum which comprises administering an angiostatically effective amount of a proteinase to a person in whom such preventing is required, sufficient to prevent formation of new vasculature required for implantation or sustenance of said fertilized ovum.

19. A method for inhibiting vascular endothelial cell migration which comprises contacting vascular endothelial cells with a molecule selected from the group consisting of cysteine proteinase, HagA protein, HagA peptide, HagA-specific enzymatic activity, HagA active site mimetic, HagA analog, and combinations thereof or DNA

A method for reducing cell-cell adhesion, cell-matrix adhesion, or both, which comprises contacting cells, matrix or both with an effective amount of a molecule selected from the group consisting of a cysteine proteinase, HagA protein, HagA peptide, HagA-specific enzymatic activity, HagA active site mimetic, HagA analog, and combinations thereof or DNA

The following is a list of the names of the persons who have been appointed to the various positions in the Department of the Interior, for the term of years indicated:

ADD  
B4